Spain Analgesics Market Report: Trends, Growth and Forecast (2026-2032)
By Product (Systemic Analgesics (Adult Analgesics, Paediatric Analgesics, Combined Systemic Analgesics), Topical Analgesics/Anaesthetic), By Drug Type (Opioid Analgesics (Strong Opioids, Weak Opioids), Non-opioid Analgesics (Acetaminophen, Aspirin, Combination Products, Diclofenac, Dipyrone, Ibuprofen, Ketoprofen, Naproxen, OTC Triptans), Compound/Combination Analgesics (Opioid + Non-Opioid Combinations, Multi-Ingredient Non-Opioid Combinations)), By Route of Administration (Oral, Parenteral/Injectable, Topical/External, Transdermal, Rectal/Other), By Pain Type (Acute Pain, Chronic Pain, Breakthrough Pain), By Application (Surgical & Post-operative Pain, Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Migraine/Headache, Dental Pain, Others), By Sales Channel (Retail Offline (Offline Pharmacies, Hospital Pharmacies), Retail Online (Online Pharmacies)), By Prescription Type (Prescription, OTC), By Formulation (Tablets, Capsules, Liquids, Injectables, Gels/Creams, Patches), By End User (Hospitals, Clinics/ASCs, Homecare) ... Read more
|
Major Players
|
Spain Analgesics Market Statistics and Insights, 2026
- Market Size Statistics
- Analgesics market size in Spain was valued at USD 460 million in 2025 and is estimated at USD 470 million in 2026.
- The market size is expected to grow to USD 510 million by 2032.
- Market to register a CAGR of around 1.48% during 2026-32.
- Product Shares
- Systemic analgesics grabbed market share of 55%.
- Competition
- More than 20 companies are actively engaged in producing analgesics in Spain.
- Top 5 companies acquired around 45% of the market share.
- Bayer Hispania SL, Viatris Inc, Reckitt Benckiser Espana SL, Haleon Spain SA, Grupo Ferrer Internacional SA etc., are few of the top companies.
- Sales Channel
- Retail offline grabbed 60% of the market.
Spain Analgesics Market Outlook
The Spain analgesics market size was valued at USD 460 million in 2025 and is projected to grow from USD 470 million in 2026 to USD 510 million by 2032, exhibiting a CAGR of around 1.48% during the forecast period. Growth is supported by steady demand for pain relief as chronic health problems remain common across the adult population. In Spain, 57.7% of people aged 15 and above live with a chronic health problem or disease, while 19.8% report chronic lower back pain, which keeps routine symptom management important.
Demand also stays broad across different consumer groups, with women showing a higher chronic disease burden than men. The same official survey shows that 62.3% of women aged 15 and above report a chronic health problem or disease, compared with 52.8% of men. This keeps analgesics relevant for day to day discomfort, especially where consumers look for practical OTC options that fit regular self care and everyday use.
At the same time, medicine availability remains an important challenge because supply tensions continue across the healthcare system. Spanish Agency of Medicines and Medical Devices (AEMPS) reports 1,194 supply incidents in the first half of 2025, while 3.64% of 32,812 authorised medicine presentations had supply problems during the period. In analgesics, this can affect continuity of product access in pharmacies, even though the category continues to see stable baseline demand.
Within the category, systemic analgesics hold the highest product share at around 55%, supported by broad use for headache, dental pain, back pain, menstrual pain, and fever. Retail offline leads sales channels with around 60% share, reflecting the continued importance of physical pharmacies for routine purchase decisions. Newer oral formats such as soft capsules are also becoming more visible, helping analgesics stay aligned with convenience led consumer preference during 2026-32.

Spain Analgesics Market Growth DriverChronic Health Burden Keeps Pain Relief Relevant
Pain relief demand stays firm in Spain because chronic health problems remain common across the adult population. Spain’s National Statistics Institute reports that 57.7% of people aged 15 and above live with a chronic health problem or disease. Among the most frequent conditions, 19.8% report chronic lower back pain, which keeps everyday symptom management important and supports steady need for analgesics used in routine self care.
The need stays broad across different consumer groups, with women showing a higher chronic disease burden than men. The same official survey shows that 62.3% of women aged 15 and above report a chronic health problem or disease, compared with 52.8% of men. This keeps regular pain relief use relevant for day to day discomfort, especially where consumers look for practical OTC options that fit daily life.
Spain Analgesics Market ChallengeSupply Constraints Keep Availability Under Pressure
Medicine availability remains a key challenge in Spain because supply tensions continue across the healthcare system. AEMPS reports that 1,194 supply incidents were recorded in the first half of 2025. It also says 3.64% of the 32,812 authorised medicine presentations had supply problems during the period. This keeps product continuity under pressure and can affect access to routine pain relief options in pharmacies.
The issue also demands constant intervention from the regulator. AEMPS says 801 actions were carried out to prevent or minimise the impact of these shortages in the first half of 2025. Although the situation improves year on year, the agency notes that the volume remains structurally above levels seen before 2022. This means analgesics suppliers still need stronger planning, sourcing discipline, and inventory management.
Unlock Market Intelligence
Explore the market potential with our data-driven report
Spain Analgesics Market TrendConvenient Oral Formats Gain Visibility
Convenience led oral formats are becoming more visible in Spain’s pain relief space. AEMPS records show that Ibuprofeno rapid Stadacare 400 mg cápsulas blandas receives its first authorisation in September 2025. The same technical sheet states that the product is presented as a soft capsule and is indicated for the short term treatment of mild to moderate pain and fever in adults and adolescents aged 12 years and above.
The format also reflects a stronger focus on faster and easier use. AEMPS states that the median time to peak plasma concentration in the fasting state is 40 minutes for ibuprofen soft capsules versus 90 minutes for standard ibuprofen tablets. This makes more convenient and quicker acting systemic analgesics increasingly visible in consumer choice and product development.
Spain Analgesics Market OpportunityDomestic Production Support Opens New Room
Stronger policy support for medicine availability is creating room for more local manufacturing in Spain. On 24 June 2025, AEMPS published its 2025-2030 Plan to Guarantee the Supply of Human Medicines. The agency says the plan includes measures to detect vulnerabilities and dependencies on third countries in the production of medicines and strategic active ingredients. This creates a better base for expanding domestic supply capacity.
The opportunity becomes clearer because the plan also proposes incentives to encourage production in national territory and faster regulatory support for strategic medicines. AEMPS further notes that Spain was the first European country to create a Strategic Medicines List in 2022, which now supports protection and availability measures. This gives analgesics producers more room to benefit from localisation and supply security initiatives.
Unlock Market Intelligence
Explore the market potential with our data-driven report
Spain Analgesics Market Segmentation Analysis
By Product
- Systemic Analgesics
- Adult Analgesics
- Paediatric Analgesics
- Combined Systemic Analgesics
- Topical Analgesics/Anaesthetic
The segment with the highest share under the product category is systemic analgesics, accounting for around 55% of the Spain analgesics market. This position is leading because such oral pain relievers can be readily accessed to relieve pain due to headaches, tooth pain, backache, menstrual pain, and fever. The reason why these products are used so commonly is because it is easy to take them and they align with routine self care for everyday discomforts.
The continued popularity of this segment is due in large part to the growing number of products being developed within the category that improve convenience and speed of administration. This will allow consumers to spend more time enjoying their lives by quickly relieving their mild to moderate pain through the consumption of systemic analgesics, especially since consumers will be able to access the same brand of systemic analgesics at any pharmacy due to their familiarity with the active ingredients and the affordable cost of these items continue to support the regular use of systemic analgesics until 2026-32.

By Sales Channel
- Retail Offline
- Offline Pharmacies
- Hospital Pharmacies
- Retail Online
- Online Pharmacies
The segment with the highest share under the sales channel category is retail offline, holding around 60% of the Spain analgesics market. This leadership is supported by the continued importance of physical pharmacies for medicine access, especially when consumers compare OTC options with prescription or reimbursed alternatives. Store based purchase remains important for routine pain relief because buyers value convenience, pharmacist guidance, and immediate product availability.
Its dominance is also linked with the way analgesics are bought in everyday care, where familiar channels remain central to product selection. Even as new products appear, offline pharmacy retail continues to stay ahead because it supports trusted purchase decisions and broad access across baseline pain relief needs during 2026-32.
List of Companies Covered in Spain Analgesics Market
The companies listed below are highly influential in the Spain analgesics market, with a significant market share and a strong impact on industry developments.
- Bayer Hispania SL
- Viatris Inc
- Reckitt Benckiser Espana SL
- Haleon Spain SA
- Grupo Ferrer Internacional SA
- Uriach-Aquilea OTC SL
- Chiesi Espana SA
- Zambon Espana SA
- Newline Pharma SLU
- Laboratorios Vinas SA
Competitive Landscape
In 2025, analgesics in Spain recorded only modest retail value growth due to reduced incidence of influenza and COVID-19 compared to previous years and constrained consumer purchasing power, which encouraged greater reliance on reimbursed prescription options such as acetaminophen, limiting OTC demand. Negative publicity surrounding metamizole, including safety concerns and reported adverse effects, supported a shift towards alternative OTC analgesics. Haleon Spain SA led the market with a 15.5% value share, followed by Grupo Ferrer Internacional SA at 12.0%, with leading brands including Voltadol and Gelocatil across topical and systemic segments. Despite stable baseline demand, supply shortages, particularly in paediatric and paracetamol products due to reliance on imported active ingredients, constrained growth, while innovation through new product launches and increasing interest in segments such as naproxen and sports injury-related pain relief supported gradual market development.
Frequently Asked Questions
Related Report
- Market Segmentation
- Research Scope
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Spain Analgesics Market Policies, Regulations, and Standards
- Spain Analgesics Market Dynamics
- Growth Factors
- Challenges
- Trends
- Opportunities
- Spain Analgesics Market Statistics, 2022-2032F
- Market Size & Growth Outlook
- By Revenues in USD Million
- Market Segmentation & Growth Outlook
- By Product
- Systemic Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Adult Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Paediatric Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Combined Systemic Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Topical Analgesics/Anaesthetic- Market Insights and Forecast 2022-2032, USD Million
- Systemic Analgesics- Market Insights and Forecast 2022-2032, USD Million
- By Drug Type
- Opioid Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Strong Opioids- Market Insights and Forecast 2022-2032, USD Million
- Weak Opioids- Market Insights and Forecast 2022-2032, USD Million
- Non-opioid Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Acetaminophen- Market Insights and Forecast 2022-2032, USD Million
- Aspirin- Market Insights and Forecast 2022-2032, USD Million
- Combination Products- Market Insights and Forecast 2022-2032, USD Million
- Diclofenac- Market Insights and Forecast 2022-2032, USD Million
- Dipyrone- Market Insights and Forecast 2022-2032, USD Million
- Ibuprofen- Market Insights and Forecast 2022-2032, USD Million
- Ketoprofen- Market Insights and Forecast 2022-2032, USD Million
- Naproxen- Market Insights and Forecast 2022-2032, USD Million
- OTC Triptans- Market Insights and Forecast 2022-2032, USD Million
- Compound/Combination Analgesics- Market Insights and Forecast 2022-2032, USD Million
- Opioid + Non-Opioid Combinations- Market Insights and Forecast 2022-2032, USD Million
- Multi-Ingredient Non-Opioid Combinations- Market Insights and Forecast 2022-2032, USD Million
- Opioid Analgesics- Market Insights and Forecast 2022-2032, USD Million
- By Route of Administration
- Oral- Market Insights and Forecast 2022-2032, USD Million
- Parenteral/Injectable- Market Insights and Forecast 2022-2032, USD Million
- Topical/External- Market Insights and Forecast 2022-2032, USD Million
- Transdermal- Market Insights and Forecast 2022-2032, USD Million
- Rectal/Other- Market Insights and Forecast 2022-2032, USD Million
- By Pain Type
- Acute Pain- Market Insights and Forecast 2022-2032, USD Million
- Chronic Pain- Market Insights and Forecast 2022-2032, USD Million
- Breakthrough Pain- Market Insights and Forecast 2022-2032, USD Million
- By Application
- Surgical & Post-operative Pain- Market Insights and Forecast 2022-2032, USD Million
- Musculoskeletal Pain- Market Insights and Forecast 2022-2032, USD Million
- Neuropathic Pain- Market Insights and Forecast 2022-2032, USD Million
- Cancer Pain- Market Insights and Forecast 2022-2032, USD Million
- Migraine/Headache- Market Insights and Forecast 2022-2032, USD Million
- Dental Pain- Market Insights and Forecast 2022-2032, USD Million
- Others- Market Insights and Forecast 2022-2032, USD Million
- By Sales Channel
- Retail Offline- Market Insights and Forecast 2022-2032, USD Million
- Offline Pharmacies- Market Insights and Forecast 2022-2032, USD Million
- Hospital Pharmacies- Market Insights and Forecast 2022-2032, USD Million
- Retail Online- Market Insights and Forecast 2022-2032, USD Million
- Online Pharmacies- Market Insights and Forecast 2022-2032, USD Million
- Retail Offline- Market Insights and Forecast 2022-2032, USD Million
- By Prescription Type
- Prescription- Market Insights and Forecast 2022-2032, USD Million
- OTC- Market Insights and Forecast 2022-2032, USD Million
- By Formulation
- Tablets- Market Insights and Forecast 2022-2032, USD Million
- Capsules- Market Insights and Forecast 2022-2032, USD Million
- Liquids- Market Insights and Forecast 2022-2032, USD Million
- Injectables- Market Insights and Forecast 2022-2032, USD Million
- Gels/Creams- Market Insights and Forecast 2022-2032, USD Million
- Patches- Market Insights and Forecast 2022-2032, USD Million
- By End User
- Hospitals- Market Insights and Forecast 2022-2032, USD Million
- Clinics/ASCs- Market Insights and Forecast 2022-2032, USD Million
- Homecare- Market Insights and Forecast 2022-2032, USD Million
- By Competitors
- Competition Characteristics
- Market Share & Analysis
- By Product
- Market Size & Growth Outlook
- Spain Systemic Analgesics Market Statistics, 2022-2032
- Market Size & Growth Outlook
- By Revenues in USD Million
- Market Segmentation & Growth Outlook
- By Drug Type- Market Insights and Forecast 2022-2032, USD Million
- By Route of Administration- Market Insights and Forecast 2022-2032, USD Million
- By Pain Type- Market Insights and Forecast 2022-2032, USD Million
- By Application- Market Insights and Forecast 2022-2032, USD Million
- By Sales Channel- Market Insights and Forecast 2022-2032, USD Million
- By Prescription Type- Market Insights and Forecast 2022-2032, USD Million
- By Formulation- Market Insights and Forecast 2022-2032, USD Million
- By End User- Market Insights and Forecast 2022-2032, USD Million
- Market Size & Growth Outlook
- Spain Topical Analgesics/Anaesthetic Market Statistics, 2022-2032
- Market Size & Growth Outlook
- By Revenues in USD Million
- Market Segmentation & Growth Outlook
- By Drug Type- Market Insights and Forecast 2022-2032, USD Million
- By Route of Administration- Market Insights and Forecast 2022-2032, USD Million
- By Pain Type- Market Insights and Forecast 2022-2032, USD Million
- By Application- Market Insights and Forecast 2022-2032, USD Million
- By Sales Channel- Market Insights and Forecast 2022-2032, USD Million
- By Prescription Type- Market Insights and Forecast 2022-2032, USD Million
- By Formulation- Market Insights and Forecast 2022-2032, USD Million
- By End User- Market Insights and Forecast 2022-2032, USD Million
- Market Size & Growth Outlook
- Competitive Outlook
- Company Profiles
- Haleon Spain SA
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Grupo Ferrer Internacional SA
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Uriach-Aquilea OTC SL
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Chiesi Espana SA
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Zambon Espana SA
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Bayer Hispania SL
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Viatris Inc
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Reckitt Benckiser Espana SL
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Newline Pharma SLU
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Laboratorios Vinas SA
- Business Description
- Product Portfolio
- Collaborations & Alliances
- Recent Developments
- Financial Details
- Others
- Haleon Spain SA
- Company Profiles
- Disclaimer
| Segment | Sub-Segment |
|---|---|
| By Product |
|
| By Drug Type |
|
| By Route of Administration |
|
| By Pain Type |
|
| By Application |
|
| By Sales Channel |
|
| By Prescription Type |
|
| By Formulation |
|
| By End User |
|
Research Methodology
This study followed a structured approach comprising four key phases to assess the size and scope of the electro-oxidation market. The process began with thorough secondary research to collect data on the target market, related markets, and broader industry context. These findings, along with preliminary assumptions and estimates, were then validated through extensive primary research involving industry experts from across the value chain. To calculate the overall market size, both top-down and bottom-up methodologies were employed. Finally, market segmentation and data triangulation techniques were applied to refine and validate segment-level estimations.
Secondary Research
The secondary research phase involved gathering data from a wide range of credible and published sources. This step helped in identifying industry trends, defining market segmentation, and understanding the market landscape and value chain.
Sources consulted during this phase included:
- Company annual reports, investor presentations, and press releases
- Industry white papers and certified publications
- Trade directories and market-recognized databases
- Articles from authoritative authors and reputable journals
- Gold and silver standard websites
Secondary research was critical in mapping out the industry's value chain and monetary flow, identifying key market segments, understanding regional variations, and tracking significant industry developments.
Other key sources:
- Financial disclosures
- Industry associations and trade bodies
- News outlets and business magazines
- Academic journals and research studies
- Paid industry databases
Primary Research
To validate secondary data and gain deeper market insights, primary research was conducted with key stakeholders across both the supply and demand sides of the market.
On the demand side, participants included decision-makers and influencers from end-user industries—such as CIOs, CTOs, and CSOs—who provided first-hand perspectives on market needs, product usage, and future expectations.
On the supply side, interviews were conducted with manufacturers, industry associations, and institutional participants to gather insights into current offerings, product pipelines, and market challenges.
Primary interviews provided critical inputs such as:
- Market size and revenue data
- Product and service breakdowns
- Market forecasts
- Regional and application-specific trends
Stakeholders consulted included:
- Leading OEM and solution providers
- Channel and distribution partners
- End users across various applications
- Independent consultants and industry specialists
Market Size Estimation and Data Triangulation
- Identifying Key Market Participants (Secondary Research)
- Goal: To identify the major players or companies in the target market. This typically involves using publicly available data sources such as industry reports, market research publications, and financial statements of companies.
- Tools: Reports from firms like Gartner, Forrester, Euromonitor, Statista, IBISWorld, and others. Public financial statements, news articles, and press releases from top market players.
- Extracting Earnings of Key Market Participants
- Goal: To estimate the earnings generated from the product or service being analyzed. This step helps in understanding the revenue potential of each market player in a specific geography.
- Methods: Earnings data can be gathered from:
- Publicly available financial reports (for listed companies).
- Interviews and primary data sources from professionals, such as Directors, VPs, SVPs, etc. This is especially useful for understanding more nuanced, internal data that isn't publicly disclosed.
- Annual reports and investor presentations of key players.
- Data Collation and Development of a Relevant Data Model
- Goal: To collate inputs from both primary and secondary sources into a structured, data-driven model for market estimation. This model will incorporate key market KPIs and any independent variables relevant to the market.
- Key KPIs: These could include:
- Market size, growth rate, and demand drivers.
- Industry-specific metrics like market share, average revenue per customer (ARPC), or average deal size.
- External variables, such as economic growth rates, inflation rates, or commodity prices, that could affect the market.
- Data Modeling: Based on this data, the market forecasts are developed for the next 5 years. A combination of trend analysis, scenario modeling, and statistical regression might be used to generate projections.
- Scenario Analysis
- Goal: To test different assumptions and validate how sensitive the market is to changes in key variables (e.g., market demand, regulatory changes, technological disruptions).
- Types of Scenarios:
- Base Case: Based on current assumptions and historical data.
- Best-Case Scenario: Assuming favorable market conditions, regulatory environments, and technological advancements.
- Worst-Case Scenario: Accounting for adverse factors, such as economic downturns, stricter regulations, or unexpected disruptions.











